BML Capital Management, LLC
In its 13F for Q4 2024 (holdings as of December 31, 2024, filed February 7, 2025), BML Capital Management, LLC reported 25 stock positions worth $161.0 million. Its top holding was Aclaris Therapeutics (ACRS) at 22.0% of the portfolio, followed by iShares 0-3 Month Treasury B (SGOV, 16.2%) and Atea Pharmaceuticals (AVIR, 15.8%). Compared with Q3 2024, it opened 4 new positions, sold out of 8, added to 7 and reduced 5. The biggest buy was a new position in Essa Pharma (EPIX) and the biggest sale an exit from SS SPDR BB 1-3M T-Bill ETF (BIL).
- Most Recent 13F
- Q2 2026
- Location
- ZIONSVILLE, IN
- CIK
- 0001616824
- Portfolio Value
- $161.0M (Q4 2024)
- SEC Filing
- 0001754960-25-000111 ↗ filed Feb 7, 2025
Holdings Value
Holdings 25 stocks · $161.0M
| ACRS Aclaris Therapeutics Inc. | 21.95% | 14,250,000 | $35.3M | No change |
| SGOV iShares 0-3 Month Treasury B | 16.20% | 260,000 | $26.1M | Reduce -3.7% |
| AVIR Atea Pharmaceuticals Inc. | 15.83% | 7,608,312 | $25.5M | Add +14.4% |
| ADVM Adverum Biotechnologies Inc. | 6.58% | 2,268,064 | $10.6M | No change |
| ANTX AN2 Therapeutics Inc. | 4.93% | 5,749,432 | $7.9M | No change |
| TIL Instil Bio Inc. | 4.74% | 400,000 | $7.6M | Add +19.4% |
| EPIX Essa Pharma Inc. | 4.69% | 4,221,546 | $7.6M | New |
| WHWK Whitehawk Therapeutics Inc. filed as AADI BIOSCIENCE INC | 4.12% | 2,100,000 | $6.6M | Add +5.0% |
| ORMP Oramed Pharmaceuticals Inc. | 3.97% | 2,643,907 | $6.4M | Add +20.9% |
| IKENA ONCOLOGY INC | 3.65% | 3,585,866 | $5.9M | Add +395.8% |
| PMVP PMV Pharmaceuticals Inc. | 3.25% | 3,466,684 | $5.2M | Add +105.3% |
| ACHL Achilles Therapeutics PL-ADR | 2.90% | 4,100,002 | $4.7M | No change |
| CNTB Connect Biopharma Hldgs Ltd. | 1.79% | 2,093,232 | $2.9M | No change |
| MIST Milestone Pharmaceuticals Inc. | 1.67% | 1,136,091 | $2.7M | No change |
| ATHIRA PHARMA INC | 1.01% | 2,775,885 | $1.6M | New |
| ASTC Astrotech Corp. | 0.92% | 220,410 | $1.5M | No change |
| LSTA Lisata Therapeutics Inc. | 0.53% | 284,669 | $848K | No change |
| PVLA Palvella Therapeutics Inc. | 0.31% | 42,130 | $506K | New |
| VTGN Vistagen Therapeutics Inc. | 0.27% | 150,000 | $443K | No change |
| KZR Kezar Life Sciences Inc. | 0.20% | 48,668 | $327K | New |
| LENZ Lenz Therapeutics Inc. | 0.17% | 9,271 | $268K | Reduce -84.5% |
| NXTC Nextcure Inc. | 0.13% | 273,536 | $211K | Reduce -1.1% |
| VRCA Verrica Pharmaceuticals Inc. | 0.08% | 174,651 | $122K | Reduce -3.0% |
| ALLOVIR INC | 0.05% | 184,246 | $77K | Reduce -69.5% |
| HLVX Hillevax Inc. | 0.03% | 20,760 | $43K | Add +5.1% |
Portfolio Sells Q3 2024 → Q4 2024
| BIL SS SPDR BB 1-3M T-Bill ETF | Sold out | 0.00% | −9.45 |
| TECX Tectonic Therapeutic Inc. | Sold out | 0.00% | −3.78 |
| RENEO PHARMACEUTICALS INC | Sold out | 0.00% | −3.46 |
| LENZ Lenz Therapeutics Inc. | Reduce -84.5% | 0.17% | −0.67 |
| VNDA Vanda Pharmaceuticals Inc. | Sold out | 0.00% | −0.63 |
| PIERIS PHARMACEUTICALS INC | Sold out | 0.00% | −0.41 |
| CALC Calcimedica Inc. | Sold out | 0.00% | −0.40 |
| TLIS Talis Biomedical Corp. | Sold out | 0.00% | −0.27 |
| ALLOVIR INC | Reduce -69.5% | 0.05% | −0.24 |
| FBRX Forte Biosciences Inc. | Sold out | 0.00% | −0.23 |
| NXTC Nextcure Inc. | Reduce -1.1% | 0.13% | −0.09 |
| VRCA Verrica Pharmaceuticals Inc. | Reduce -3.0% | 0.08% | −0.08 |
| SGOV iShares 0-3 Month Treasury B | Reduce -3.7% | 16.20% | +0.20 |
Portfolio Buys Q3 2024 → Q4 2024
| EPIX Essa Pharma Inc. | New | 4.69% | +4.69 |
| IKENA ONCOLOGY INC | Add +395.8% | 3.65% | +2.92 |
| AVIR Atea Pharmaceuticals Inc. | Add +14.4% | 15.83% | +2.73 |
| PMVP PMV Pharmaceuticals Inc. | Add +105.3% | 3.25% | +1.77 |
| WHWK Whitehawk Therapeutics Inc. | Add +5.0% | 4.12% | +1.69 |
| ATHIRA PHARMA INC | New | 1.01% | +1.01 |
| ORMP Oramed Pharmaceuticals Inc. | Add +20.9% | 3.97% | +0.84 |
| PVLA Palvella Therapeutics Inc. | New | 0.31% | +0.31 |
| KZR Kezar Life Sciences Inc. | New | 0.20% | +0.20 |
| HLVX Hillevax Inc. | Add +5.1% | 0.03% | +0.01 |
| TIL Instil Bio Inc. | Add +19.4% | 4.74% | −8.53 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 15 | $175.1M | ACRS, AVIR, ENGN, KHC, OM |
| Q1 2026 | 15 | $155.4M | ACRS, AVIR, ORMP, TLYS, OM |
| Q4 2025 | 13 | $113.0M | ACRS, AVIR, ORMP, TIL, PMVP |
| Q3 2025 | 19 | $108.7M | ACRS, AVIR, ADVM, TIL, ORMP |
| Q2 2025 | 23 | $130.5M | AVIR, THRD, ACRS, TIL, EPIX |
| Q1 2025 | 27 | $123.6M | AVIR, ACRS, THRD, ADVM, ANTX |
| Q4 2024 | 25 | $161.0M | ACRS, SGOV, AVIR, ADVM, ANTX |
| Q3 2024 | 29 | $169.9M | SGOV, TIL, AVIR, ACRS, BIL |
| Q2 2024 | 27 | $136.5M | SGOV, AVIR, BIL, ACRS, ADVM |
| Q1 2024Amended | 30 | $149.4M | SGOV, AVIR, BIL, ADVM, ACRS |